You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

Litigation Details for Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2019)

✉ Email this page to a colleague

« Back to Dashboard

Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2019)

Docket	⤷ Sign Up	Date Filed	2019-10-29
Court	District Court, D. Delaware	Date Terminated	2023-01-30
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To	Sherry R. Fallon
Parties	EXELIXIS, INC.; MSN PHARMACEUTICALS INC.
Patents	10,034,873; 10,039,757; 7,579,473; 8,497,284; 8,877,776; 9,724,342
Attorneys	Dominick T. Gattuso; Richard Juang
Firms	Heyman Enerio Gattuso & Hirzel LLP; Stamoulis & Weinblatt LLC
Link to Docket	External link to docket

Small Molecule Drugs cited in Exelixis, Inc. v. MSN Laboratories Private Limited

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up and ⤷ Sign Up .

Details for Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2019)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2019-10-29	1	Complaint	BACKGROUND 18. U.S. Patent No. 8,877,776 (“the ’776 Patent”), entitled “(L)-malate salt of…Product”) prior to the expiration of U.S. Patent No. 8,877,776. … INFRINGEMENT OF US PATENT NO. 8,877,776 28. Exelixis incorporates each…FOR PATENT INFRINGEMENT 1. This is an action for patent infringement under the patent laws…November 4, 2014. The ’776 Patent will expire on October 8, 2030. The ’776 Patent claims crystalline Form	External link to document
2021-09-08	196	Notice of Service	Initial Invalidity Contentions for U.S. Patent Nos. 7,579,473 and 8,497,284 [CONFIDENTIAL] filed by MSN…2019 30 January 2023 1:19-cv-02017 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2021-09-08	197	Notice of Service	Initial Invalidity Contentions for U.S. Patent No. 8,877,776 (with Exhibit A) [HIGHLY CONFIDENTIAL]; …2019 30 January 2023 1:19-cv-02017 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2021-09-08	198	Notice of Service	Infringement Contentions Concerning U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284, and (3) Exelixis …Supplemental Infringement Contentions Concerning U.S. Patent No. 8,877,776 filed by Exelixis, Inc..(Raucci, …2019 30 January 2023 1:19-cv-02017 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.